Transmission and Clinical Characteristics of Asymptomatic Patients With SARS-CoV-2 Infection

Tan, Jie; Liu, Shousheng; Zhuang, Likun; Chen, Lizhen; Dong, Mingjie; Zhang, Jie; Xin, Yongning

doi:10.2217/fvl-2020-0087

Cited by 53 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this report, we describe some asymptomatic carriers of the disease. Healthy asymptomatic carriers are more likely to be younger (median age: 34.5 years) than symptomatic hospitalized patients (median age: 56.0 years) ( 10 ), which is consistent with some recent studies ( 11 ). RNA tests of nasopharyngeal swabs were 100% positive, which is much higher than the positive rate in stool and urine specimens in asymptomatic carriers, suggesting that nasopharyngeal swabs could be the optimum samples.…”

Section: Discussionsupporting

confidence: 90%

“…RNA tests of nasopharyngeal swabs were 100% positive, which is much higher than the positive rate in stool and urine specimens in asymptomatic carriers, suggesting that nasopharyngeal swabs could be the optimum samples. However, the nasopharyngeal swabs test was reported to deliver false negatives because of sample collection and the operating procedures in some studies ( 11 ). All asymptomatic carriers presented with elevated IgG antibody levels, while the IgM antibody levels were slightly elevated in a few patients in our study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China

et al. 2020

View full text Add to dashboard Cite

We report the clinical characteristics, viral shedding duration, and contact tracing for asymptomatic carriers of SARS-CoV-2 in Wuhan, China. The asymptomatic carriers were relatively young (median age: 34.5 years). Chest computed tomography showed no abnormalities. The nasopharyngeal swab was an optimum specimen for RNA testing. The median viral shedding duration was 11.5 days. Notably, 2 months of viral shedding duration were reported in two nurses, which was much longer than previously reported or than usually thought. The transmissibility of SARS-CoV-2 by asymptomatic carriers during the studied period in Wuhan appeared to be weak. Only one patient (1/12) was found to have transmitted the virus to another person. Early asymptomatic carrier detection, isolation, and contact tracing could be useful to mitigate the spread of the disease.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID-19) is a respiratory illness of variably severity; ranging from asymptomatic infection to mild infection, with fever and cough to severe pneumonia and acute respiratory distress 1 . Current reports suggest that asymptomatic spread is substantial 2 , and SARS-CoV-2 infection induces a transient antibody response in most individuals 3 . Therefore, development of successful interventions is an immediate requirement to protect the global population against infection and transmission of this virus and its associated clinical and societal consequences.…”

Section: Introductionmentioning

confidence: 99%

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

Moore

Dora

Peinovich

et al. 2020

Preprint

View full text Add to dashboard Cite

There is an urgent need to develop efficacious vaccines against SARS-CoV-2 that also address the issues of deployment, equitable access, and vaccine acceptance. Ideally, the vaccine would prevent virus infection and transmission as well as preventing COVID-19 disease. We previously developed an oral adenovirus-based vaccine technology that induces both mucosal and systemic immunity in humans. Here we investigate the immunogenicity of a range of candidate adenovirus-based vaccines, expressing full or partial sequences of the spike and nucleocapsid proteins, in mice. We demonstrate that, compared to expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. Antigen-specific CD4+ and CD8+ T cells were induced by this leading vaccine candidate at low and high doses. This full-length spike antigen plus nucleocapsid adenovirus construct has been prioritized for further clinical development.

show abstract

“…The basic reproduction number (R0) for SARS-CoV-2 infection before the implementation of mitigation strategies is estimated to range from approximately 2.0 to 3.6 [7][8][9][10][11][12], with a high risk for transmission because of high numbers of asymptomatic subjects and emerging clusters [13][14][15]. Transmission models based on real-world epidemiological data are important tools for understanding the dynamics of SARS-CoV-2 transmission and can be useful to guide mitigation strategies and policy decisions designed to assist patients with COVID-19 and reduce disease spread [9, [16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

A COVID-19 transmission model informing medication development and supply chain needs

Lemenuel‐Diot

Clinch

Hurt

et al. 2020

Preprint

View full text Add to dashboard Cite

Accurate prediction of COVID-19 cases can optimize clinical trial recruitment, inform mitigation strategies and facilitate rapid medication development. Here we present a country-specific, modified Susceptible, Exposed, Infectious, Removed (SEIR) model of SARS-CoV-2 transmission using data from the Johns Hopkins University COVID-19 Dashboard. Inter-country differences in initial exposure, cultural/environmental factors, reporting requirements and stringency of mitigation strategies were incorporated. Asymptomatic patients and super-spreaders were also factored into our model. Using these data, our model estimated 65.8% of cases as asymptomatic; symptomatic and asymptomatic people were estimated to infect 2.12 and 5.83 other people, respectively. An estimated 9.55% of cases were super-spreaders with a 2.11-fold higher transmission rate than average. Our model estimated a mean maximum infection rate of 0.927 cases/day (inter-country range, 0.63-1.41) without mitigation strategies. Mitigation strategies with a stringency index value of ≥60% were estimated to be required to reduce the reproduction ratio below 1. It was predicted that cases over the next 2 months would differ between countries, with certain countries likely to experience an accelerated accumulation of cases. Together, results from our model can guide distribution of diagnostic tests, impact clinical trial development, support medication development and distribution and inform mitigation strategies to reduce COVID-19 spread.

show abstract

Transmission and Clinical Characteristics of Asymptomatic Patients With SARS-CoV-2 Infection

Cited by 53 publications

References 33 publications

Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China

Viral Transmission and Clinical Features in Asymptomatic Carriers of SARS-CoV-2 in Wuhan, China

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

A COVID-19 transmission model informing medication development and supply chain needs

Contact Info

Product

Resources

About